Accessibility StatementSkip Navigation NUTX Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ -- Nutex Health Inc. (NASDAQ: NUTX), a publicly traded operator of micro-hospitals and healthcare facilities, is under legal scrutiny following a class-action lawsuit that accuses the company of orchestrating a deceptive billing strategy to artificially boost its financial results. The litigation, filed in a Texas federal court, alleges that Nutex collaborated with ...

SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nutex Health Inc. (NASDAQ: NUTX), a publicly traded operator of micro-hospitals and healthcare facilities, is under legal scrutiny following a class-action lawsuit that accuses the company of orchestrating a deceptive billing strategy to artificially boost its financial results. The litigation, filed in a Texas federal court, alleges that Nutex collaborated with third-party billing firm HaloMD to submit ineligible insurance claims, misleading shareholders and ...

Core Viewpoint - Nutex Health Inc. is facing legal scrutiny due to a class-action lawsuit alleging deceptive billing practices aimed at inflating financial results, involving collaboration with a third-party billing firm, HaloMD [1][2]. Group 1: Allegations and Legal Actions - The lawsuit claims Nutex and HaloMD exploited the insurance arbitration process by submitting thousands of questionable claims, falsely certifying their validity to obtain excessive reimbursements [2]. - A report by activist short-seller Blue Orca Capital accused HaloMD of a fraudulent scheme to extract millions from insurers, leading to significant market fallout and a drop in Nutex's stock price by over 10% [3][4]. - The class-action suit seeks damages for investors misled by Nutex's public disclosures during the alleged misrepresentation period [10]. Group 2: Financial Reporting and Internal Controls - Nutex is accused of misrepresenting its progress in addressing internal control deficiencies, particularly in misclassifying stock-based compensation obligations, which distorted its financial position [5]. - Following a delay in submitting its Form 10-Q due to "non-cash accounting adjustments," Nutex's shares fell by 16.39%, closing at $92.91 [6]. - An Audit Committee found that prior financial statements required restatement due to incorrect classification of obligations related to hospital development [7]. Group 3: Investor Response and Investigations - Hagens Berman is investigating the claims against Nutex, focusing on whether the company's business model relied on questionable arbitration tactics and misleading financial reporting [11]. - The firm encourages investors who suffered losses to submit their claims and is examining the potential for recovery [11].

Core Viewpoint - Nutex Health Inc. is facing legal challenges due to a class-action lawsuit alleging deceptive billing practices that artificially inflated its financial results [1][2][9]. Group 1: Legal Allegations - The lawsuit claims Nutex collaborated with HaloMD to submit ineligible insurance claims, misleading shareholders and causing significant financial losses [1][2]. - Allegations include a systematic effort to exploit the insurance arbitration process, with thousands of questionable claims submitted to extract outsized reimbursements [2][3]. - The lawsuit asserts that Nutex's revenue model is unstable and that financial statements did not accurately reflect the company's operations [2]. Group 2: Market Reaction - Following the release of a report by Blue Orca Capital, which accused HaloMD of a fraudulent scheme, Nutex's stock dropped over 10% [3][4]. - After Nutex announced a delay in its Form 10-Q filing, shares plunged 16.39%, closing at $92.91 [6]. Group 3: Financial Reporting Issues - Nutex is accused of misrepresenting its internal control progress, particularly in misclassifying stock-based compensation obligations [5]. - The Audit Committee determined that prior financial statements required restatement due to incorrect classification of obligations related to hospital development [7]. Group 4: Investor Impact - The class-action suit seeks damages for investors who acquired Nutex securities during the alleged misrepresentation period, claiming public disclosures were materially misleading [9]. - Hagens Berman is investigating whether Nutex's business model relied on questionable arbitration tactics and if its financial reporting misled investors [10].

Core Viewpoint - Nutex Health Inc. is facing significant legal challenges while preparing to release its quarterly earnings, with mixed financial metrics indicating both potential and risk for investors [1][2][6]. Financial Performance - The company is expected to report an earnings per share (EPS) of -$5.43 and projected revenue of approximately $210.89 million for the upcoming quarter [1][6]. - Nutex has a price-to-earnings (P/E) ratio of approximately 6.84, suggesting a low market valuation of its earnings [4][6]. - The price-to-sales ratio stands at about 0.74, indicating a relatively low valuation compared to its sales [4][6]. - The enterprise value to sales ratio is 1.15, which is slightly higher than its total sales [4]. Legal Challenges - The company is currently involved in a class-action lawsuit for alleged securities law violations, with a deadline of October 21, 2025, for investors to file as lead plaintiffs [2][6]. - Allegations include fraudulent activities and misleading investors about the company's financial health, particularly through deceptive billing strategies linked to its vendor HaloMD [2][3]. Financial Health Indicators - Nutex's earnings yield is reported at 14.63%, indicating a potential return on investment for shareholders [5][6]. - The debt-to-equity ratio is 1.73, reflecting significant debt usage compared to equity [5]. - A current ratio of 2.27 suggests a strong ability to cover short-term liabilities with short-term assets, providing some reassurance to investors despite ongoing legal issues [5].

Core Viewpoint - Nutex Health Inc. is facing legal scrutiny due to a class-action lawsuit alleging deceptive billing practices that artificially inflated its financial results [1][10]. Group 1: Legal Allegations - The lawsuit claims Nutex collaborated with HaloMD to submit ineligible insurance claims, misleading shareholders and causing significant financial losses [1][2]. - Allegations include a systematic effort to exploit the insurance arbitration process, submitting thousands of questionable claims to extract excessive reimbursements [2][4]. - The complaint asserts that Nutex's revenue model is unstable and that financial statements misrepresented the company's operations [3]. Group 2: Market Reaction - Following the release of a report by Blue Orca Capital accusing HaloMD of fraud, Nutex's stock dropped over 10%, indicating investor concern [4][5]. - After Nutex delayed its Form 10-Q submission, shares plummeted 16.39% the next day, closing at $92.91 [7]. Group 3: Financial Reporting Issues - The lawsuit highlights misrepresentation in Nutex's financial controls, particularly regarding the classification of stock-based compensation obligations [6]. - On August 21, Nutex disclosed that its Audit Committee found prior financial statements required restatement due to incorrect classification of obligations related to hospital development [8]. Group 4: Investor Impact - The class-action suit seeks damages for investors who acquired Nutex securities during the alleged misrepresentation period, arguing that public disclosures were materially misleading [10][11]. - Hagens Berman is investigating whether Nutex's business model relied on questionable arbitration tactics and if its financial reporting misled investors [12].